BCL2 and acute myeloid leukemia: To assess specific drug sensitivity of IDH1-mut AML cells in vitro, IDH1-mut and IDH1-wt KG1a cell clones were treated with the IDH1-mut specific inhibitor ivosidenib, the BCL2-inhibitor venetoclax, the standard chemotherapeutic agent cytarabine (araC) and the demethylating agent 5-azacytidine.